Community Practice

Racemic substitutions for single-enantiomer drugs offer new opportunities for savings.

Biologic medicines could lower spending by $153 billion by 2023.

Several pharmacy groups appealed guideline revisions.

Will be part of the U.S.’s public health emergency medical supplies and pharmaceuticals.

Online pharmacy that discovered the impurity discontinues sales.

Some pharmacies are now serving coffee and other refreshments. 

Monoclonal antibody for autoimmune and neurodegenerative disorders.

An estimated 100 million Americans lack good access to pharmacies.

Caused by lower income, insurance status, higher prices, poor transportation, long distances.

Approved forms should be considered as options for community distribution.

Now approved in 7mg and 14 mg tablets.

Layoffs highlight increasing jobs problem. 

Ensuring your pharmacy’s video marketing dusts the competition has never been more important.

Monoclonal antibody shows potential for lupus nephritis treatment.

Programs shown to improve patient outcomes, reduce antibiotic resistance, and decrease healthcare costs.

23,600 cases across 29 states since 2016.

Combination therapy for advance endometrial carcinoma.

Cost, education, self-monitoring, and more. 

Fear, one's faith in the government, and likelihood of exposure are leading factors.

Oncologists recognize the potential of artificial intelligence (AI) in improving the quality of care and patient outcomes according to new research.

Indicated as part of a three-drug oral combination.

The 2018 oncology drug market had a record number of new treatments and continued a trend of growth.

NHE3 inhibitor administered as 50 mg oral tablets.

New medications and treatment guidelines

Patients are still allowed to take medicines as prescribed.

Fentanyl, oxymorphone, and hydrocodone face greatest cuts.

"Community pharmacies have reasons to be optimistic..." writes Jhaveri. 

Eight pharmacy groups lauded a letter urging the Trump administration to reform direct and indirect remuneration (DIR) fees.